J&J DePuy Synthes Sale: Orthopedics Divestiture and MedTech Spinoff Guide

Deal at a Glance

On October 14, 2025, Johnson & Johnson (NYSE: JNJ) announced its intent to separate its Orthopaedics business — DePuy Synthes — into a standalone company. Four months later, in February 2026, Bloomberg reported that J&J was exploring a potential outright sale of the unit for more than $20 billion, opening a second path beyond the originally planned spinoff. The separation, expected to complete by mid-to-late 2027, would unwind J&J's $21.3 billion acquisition of Synthes — at the time the largest medtech deal in history.

This separation represents one of the largest corporate divestitures in medtech history and signals J&J's definitive strategic pivot away from orthopedics — a business it spent decades building — toward higher-growth segments including cardiovascular intervention and robotic surgery.

Timeline of Events

The DePuy Synthes separation has been years in the making, reflecting a gradual strategic reassessment:

• 2011–2012: J&J acquires Synthes for $21.3 billion, merging it with DePuy to form DePuy Synthes — at the time the largest medtech deal ever
• 2023: J&J implements a two-year restructuring program for the orthopedics business, exiting certain markets and discontinuing product lines. The same year, J&J spins off its $15 billion consumer health unit into Kenvue
• October 14, 2025: J&J officially announces intent to separate DePuy Synthes into a standalone company, alongside Q3 2025 earnings. Namal Nawana appointed Worldwide President
• Q3 2025 earnings: DePuy Synthes reports $2.27 billion revenue, +3.8% YoY — a rebound after nine months of -0.3% decline
• January 2026: J&J raises 2025 product revenue forecast to $93.5B–$93.9B; provides 2026 sales guidance of $99.5B–$100.5B
• February 19, 2026: Bloomberg reports J&J is exploring a sale of DePuy Synthes for $20B+, engaging PE firms and potential strategic buyers
• May 26, 2026: DePuy Synthes announces definitive agreement to acquire Gemtrack RF miniature tracking technology rights for its VELYS joint reconstruction portfolio
• Mid-2027 to late 2027: Expected completion of separation (18–24 months from October 2025 announcement)

DePuy Synthes: The Business

Financial Profile

DePuy Synthes generated approximately $9.3 billion in revenue in fiscal year 2025, making it one of the largest orthopedic device companies in the world. The business represents roughly 10% of J&J's total revenue and approximately 30% of its MedTech segment.

However, the growth trajectory tells a more nuanced story. While J&J's overall MedTech business grew 6.8% year-over-year in Q3 2025 (with cardiovascular alone surging 12.6%), DePuy Synthes managed only 3.8% growth in the same quarter after a nine-month period of slight decline. CFO Joe Wolk was direct: "In the scheme of where the other growth rates are for Johnson & Johnson's platforms, it falls a little short."

Product Portfolio

DePuy Synthes addresses the full spectrum of orthopedic care:

The standalone DePuy Synthes would serve approximately 7 million patients annually across a $50 billion+ global orthopedic market opportunity.

The VELYS Platform

The VELYS Digital Surgery portfolio represents J&J's investment in robotic-assisted orthopedic surgery — the segment that Tim Schmid, J&J MedTech's Worldwide Chairman, identified as a higher-growth area J&J wants to retain focus on. In May 2026, DePuy Synthes announced the acquisition of Gemtrack RF technology rights — miniature radiofrequency tracking technology for navigation and robotic applications across shoulder, hip, and knee reconstruction.

Notably, CFO Wolk told the Financial Times that the next phase of orthopedics innovation, including advanced robotics, was "beyond our scope and probably in better hands somewhere else" — a striking admission that J&J no longer believes it can or should lead in orthopedic technology.

Why J&J Is Divesting Orthopedics

Strategic Rationale

J&J's leadership has been candid about the reasons for the separation. CEO Joaquin Duato framed the decision as part of a long-standing commitment to portfolio optimization:

"This transaction enables Johnson & Johnson to further strengthen its focus and investment toward higher-growth areas where we can meaningfully extend and improve patient lives."

Tim Schmid was even more direct:

"We've been on a journey over the last several years to really aggressively move our portfolio into higher-growth markets... adding attractive assets such as Abiomed and Shockwave Medical in high-growth markets like cardiovascular are good examples. This decision to separate ortho is the next major step in that direction. Ortho is a great business but, frankly, one that participates in lower-growth markets. This is all about shrinking to grow faster for medtech."

The strategic logic is clear: J&J's cardiovascular business — supercharged by the $16.6 billion Abiomed acquisition (heart recovery) and the $13.1 billion Shockwave Medical acquisition (intravascular lithotripsy) — is growing at double-digit rates. Orthopedics, by contrast, is a mature, slower-growth market where DePuy Synthes has been losing market share to focused competitors like Stryker and Zimmer Biomet.

After the separation, J&J will concentrate on six growth areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision.

The Original $21.3 Billion Synthes Acquisition

J&J's acquisition of Synthes in 2011–2012 for $21.3 billion was, at the time, the largest medtech deal in history. J&J already owned DePuy (acquired years earlier), and the Synthes deal created the world's largest orthopedic device company under the combined DePuy Synthes banner.

The deal was driven by Hansjörg Wyss, Synthes's controlling shareholder and CEO, who explored a sale amid increasing regulatory and pricing pressures from the Affordable Care Act. Multiple private equity firms submitted non-binding proposals at approximately CHF 150 per share (~$17.9 billion), but J&J ultimately won with a premium offer.

Fourteen years later, the potential sale at $20 billion means J&J may recover approximately what it paid — a nominal break-even that represents a significant real-terms loss after accounting for inflation, integration costs, and the opportunity cost of capital. The Reddit r/MedicalDevices community captured the sentiment: "Bought it for 20B in 2012 and sold for 20B in 2026? Huge loss, destroyed the model, reputation and so much talent lost."

Potential Buyers and Deal Structure

Private Equity Firms

Bloomberg reports that large buyout firms are the most likely category of buyer, with multiple PE firms considering joint bids to acquire the unit. At $20 billion or more, the deal would be among the largest PE-backed healthcare transactions in history.

A PE acquisition would likely involve a leveraged buyout with significant debt financing, a strategy that would require DePuy Synthes's stable cash flows to service. The business's investment-grade balance sheet makes it an attractive LBO candidate.

Strategic Buyers

While no specific strategic buyers have been named publicly, the obvious candidates would be companies seeking to gain or expand orthopedic market share:

• Stryker: Already a top-3 orthopedic company; a deal would create dominant market position but would face significant antitrust scrutiny
• Zimmer Biomet: Could benefit from complementary product lines but would face similar antitrust challenges
• Smith & Nephew: Smaller player that could be transformed by such an acquisition
• Private equity-backed combinations: A PE firm could combine DePuy Synthes with another orthopedic asset

Spinoff vs. Sale

CFO Joe Wolk indicated that a tax-free spinoff was the primary focus but that J&J remained "open to ideas that others might have." Wolk described a spinoff as "the most time-consuming and resource-intensive approach" — suggesting that a sale to PE could be preferred if the valuation is compelling.

Wolk also noted that a public listing for DePuy Synthes was "unlikely," suggesting the standalone entity would more likely be PE-owned or merged with another private company before any future IPO.

The Broader MedTech Divestiture Trend

The DePuy Synthes separation is the latest in a wave of medtech portfolio optimization:

The pattern is consistent: diversified healthcare conglomerates are shedding slower-growth business units to concentrate capital and management attention on faster-growing segments. As one industry observer summarized: "leaner, more focused portfolios are better positioned to innovate and grow."

Leadership and Governance

Namal Nawana: Standalone CEO

J&J appointed Namal Nawana as Worldwide President of DePuy Synthes effective October 14, 2025, reporting directly to CEO Joaquin Duato. Nawana is expected to continue leading the business following the separation.

Nawana's background is uniquely suited to the standalone mandate:

• Executive Chairman and Founder, Sapphiros (consumer diagnostics)
• CEO and Board Director, Smith & Nephew Plc — direct orthopedic industry experience
• CEO and Board Director, Alere, Inc. — until acquisition by Abbott
• 15+ years at J&J in progressively senior roles, including Worldwide President of DePuy Synthes Spine

His experience running a standalone orthopedic company (Smith & Nephew) and his prior tenure at J&J's own spine division give him credibility with both the orthopedic community and J&J's leadership.

Orthopedic Market Competitive Dynamics

The separation will reshape the competitive landscape of the $50 billion+ global orthopedic device market:

Analysts have noted that DePuy Synthes has been losing market share to rivals — particularly Stryker — in recent years. A standalone DePuy Synthes, whether PE-owned or publicly traded, would need to reverse this trend through focused investment in innovation, commercial execution, and the VELYS robotic platform.

The competitive dynamics will also be affected by the transition period. As Brandon Wade, VP at Health Advances, noted, competitors may experience both "near-term volatility and long-term opportunity" during the separation process. Focused orthopedic companies like ATEC Spine have demonstrated that dedicated, smaller companies can take market share from larger, distracted competitors.

Legal and Regulatory Considerations

ASR Hip Litigation

J&J has faced thousands of lawsuits related to alleged defects in DePuy's ASR hip replacement system. As of February 2026, J&J had resolved all but approximately 128 of roughly 10,600 claims in nationwide litigation. The remaining claims represent a manageable but ongoing legal exposure that would need to be allocated in any separation transaction.

Separation Conditions

The separation is subject to several conditions:

• Consultations with works councils and employee representative bodies
• Final approval by the J&J Board of Directors
• Receipt of regulatory approvals (including potential antitrust review if sold to a strategic buyer)
• Completion of detailed financial documentation for prospective buyers

CFO Wolk indicated that no "newsworthy" updates are expected until mid-2026, suggesting that the process of engaging with potential buyers is still in its early stages.

Frequently Asked Questions

Why is J&J selling DePuy Synthes? J&J's orthopedics business generates lower growth than its other MedTech segments, particularly cardiovascular (growing 12.6% in Q3 2025). CEO Duato wants to focus J&J's investment on higher-growth areas including cardiovascular, oncology, immunology, neuroscience, and vision.

How much is DePuy Synthes worth? Bloomberg Intelligence estimates approximately $20 billion in equity value, or ~$28 billion including debt. At $9.3 billion in revenue, this implies roughly 2.1x–3.0x revenue.

Who might buy DePuy Synthes? Large private equity firms are reportedly the most likely buyers, potentially through joint bids. Strategic medical device companies could also express interest, though antitrust concerns may limit options among existing orthopedic players.

What happens to VELYS robotic surgery? The VELYS platform and the recently acquired Gemtrack RF tracking technology would transfer with DePuy Synthes in the separation. J&J has indicated that advanced orthopedic robotics is "beyond our scope" and would be better positioned in a standalone or PE-owned entity.

When will the separation be completed? J&J targets mid-2027 to late 2027 for completion (18–24 months from the October 2025 announcement). CFO Wolk said no major updates are expected until mid-2026.

How does this compare to other medtech spinoffs? The DePuy Synthes separation follows a broader industry trend that includes Medtronic's diabetes spinoff, Zimmer Biomet's ZimVie separation, BD's embecta spinoff, and Baxter's kidney care divestiture. All reflect a shift toward focused, higher-growth portfolios.